Skip to main content

Multani Pratik S's Form 4 filing

Oric Pharmaceuticals, Inc. (ORIC) · filed Dec 19, 2023

Accession no.
0001209191-23-059266
Filed
Dec 19, 2023
Trade date
Dec 15, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $45.4K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Multani Pratik SCIK 0001586894Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 15, 2023Common StockMOption exerciseAcquired+14,042$0.00F1$029,091Direct
Dec 15, 2023Common StockSSaleDisposed−5,282$8.59F4−$45,372.3823,809Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 15, 2023Common StockMOption exerciseDisposed−6,042$0.00$06,042Direct
Dec 15, 2023Common StockMOption exerciseDisposed−8,000$0.00$016,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

Referenced by the price of 1 transaction in Table I.

F4

Represents the weighted average share price of an aggregate total of 5,282 shares sold in the price range of $8.57 to $8.795 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)